Research and Development

Focus on Innovation

Our Research and Development (R&D) expertise reinforces our commitment to developing innovative, safe and effective products that cater to the unmet medical needs of patients across the globe[39]. A strong team of 3,000+ R&D professionals along with our chemistry and technological skills help us in developing a strong pipeline of specialty and complex generic products. Our R&D capabilities extend across various dosage forms, including injectables, orals, liquids, ointments, gels, sprays, hormones, and oral products. Our R&D centres undergo regular audits by multiple international regulatory authorities, ensuring compliance with stringent quality and regulatory standards. In addition to our internal efforts, we also collaborate with academia and industry experts to enhance our R&D capabilities.

FY24 R&D Highlights

₹ 31.8 Bn
In R&D investment

2,301 Patents
Granted till date

~250
Global formulation dossiers filed

3,000+ Member
Strong R&D team

Note – All facts and figures are for FY24

R&D Investments

₹ 31.8 Bn



Intellectual Property

Our intellectual property team specialises in chemistry, analytical techniques, dosage forms, and global patent practices.

As of March 31, 2024, our patent portfolio comprised 3,154 patents filed and 2,301 granted patents, reflecting our unwavering commitment to innovation and adopting cutting-edge science.

[39]GRI 3-3

Our R&D Approach and Capabilities

Enablers

- Significant investments in R&D with focus on developing specialty, complex generics, APIs, and process improvement
- Dedicated R&D team of 3,000+ professionals with state-of-the-art R&D infrastructure
- Compliant with global regulatory standards for maintaining high-quality
- Aim to create new technologies using green reagents in API synthesis, applying Process Analytical Technology (PAT) tools, and executing advanced processing techniques
- Comprehensive product life cycle management with backward integration for key products
- Enhancing operational efficiency using Quality by Design (QbD) framework and Six Sigma methodologies
- Development of innovative compact dosage forms with enhanced stability and decreased pharmacokinetic variability
- Expansion of product portfolio to cater to the evolving needs of patients

Capabilities

- Capability to develop various dosage such as orals, liquids, ointments, gels, sprays, and injectables
- Biological capabilities, chemistry skills, and new drug development capabilities
- Capability to develop non-infringing formulations and specialty/complex products
- Broad product portfolio covering multiple therapeutic segments catering to diverse patient needs
- Competencies to undertake clinical studies for specialty products and complex generics

Ambitions

- Targeted investments to expand the specialty pipeline
- Focus on developing complex generics
- Growing focus on developing the R&D pipeline for Emerging Markets and India
- Improved efforts in developing strategically important APIs
- Collaborate with academia and industry experts to enhance our R&D capabilities

Research and Development

Our Specialty R&D Pipeline (as of November 2024)

Candidate	Mechanism of Action	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Registration
Leqselvi	JAK Inhibitor	Severe alopecia areata					
Nidlegy™	Immunocytokines	Melanoma & non-melanoma skin cancers					
Ilumya	IL-23 Antagonist	Psoriatic arthritis					
Fibromun	Innovative anti-cancer immunotherapy	Soft tissue sarcoma Glioblastoma					
MM-II	Liposomal intra-articular lubrication	Pain in osteoarthritis					
SCD-044	Selective SIPR1 Agonist	Atopic dermatitis Psoriasis					
GL0034	GLP-1R Agonist	Obesity					

Note - 1. Leqselvi received USFDA approval in July
2. All molecules for global markets except Nidlegy™ where Sun Pharma is commercial partner for Europe, Australia & New Zealand. Nidlegy™ is a trademark of Philogen.

Reducing Environmental Impact through 'Green Chemistry'

The pharmaceutical industry is adopting a benign-by-design approach, employing non-toxic methods/tools/techniques/solvents for sustainable product development. Our R&D teams continuously innovate to minimise our products' ecological footprint through **'Green Chemistry'** approaches.

Steps Taken to Reduce Environmental Impact